advanced medical technologies

Exhibit ES-8: Selected Sealant Product Companies and Their Strategies

Company	Products and Prices	Strategy
Focal division of Genzyme Biosurgery	Focal Seal L $30 per ml	Available for lung resections in Europe and as an adjunct for non-hemostasis sealing in the USA. Focal exploiting light activated hydrogel IP. Focal is strategically focused on exploiting unique sealant capability of its products in neurological, cardiovascular, gastrointestinal, and thoracic applications.
Angiotech	CoStasis (Dynastat) $50 per ml	A sprayable liquid hemostat adjunct for use in surgical procedures to control bleeding in specific clinical applications. Five year agreement with Tyco for a broad range of indications in the USA, Europe, Latin America, Middle East, Australia, New Zealand, and India. Cohesion provides unique products for sealing and hemostasis targeted at the full range of surgical procedures.
Fusion Medical Acquired by Baxter	Floseal $28 per ml	Non-sealant hemostat for all hemostasis as an adjunct, including problematic bleeding. Strategy is to develop patented products which combine technologies incorporating a number of processed mammalian biomaterials and have hemostatic benefits for surgery in demanding actively bleeding procedures, and lead to rehabilitation and re-operation benefits by reducing adhesion formation.
Baxter Healthcare	Tisseel $65 per ml	Homologous pooled fibrin, human thrombin, and bovine aprotinin. Adjunct for hemostasis in an expanding range of indications. Baxter focuses on biopharmaceuticals, vaccines, biosurgery and transfusion products and provides products for medication delivery and dialysis. The bioscience division of Baxter provides innovative solutions for biosurgery, tissue regeneration and surgical hemostasis.
CryoLife	Bioglue $45 per ml	Haemostatic adjunct for aortic dissection during surgery and may also be used during lung procedures; contains proprietary mixture of bovine albumin and glutaraldehyde. CryoLife focuses on providing donated human tissue for surgical procedures. Recently has focused on developing synthetic and engineered products as replacements for donated tissue. CryoLife will continue to target Bioglue at procedures which require a strong hemostatic tissue sealant, and compete on product benefits with Tisseel etc.
Haemacure	Haemaseel $65 per ml	Hemostat adjunct identical to Tisseel. Strategy to become a fully integrated supplier of haemostatic and sealant products and to evolve these into new uses such as drug delivery.

Source: MedMarket Diligence, LLC

From “Worldwide Surgical Sealants, Glues and Wound Closure Market, 2007-2011,” published February 2007. Click for details.

This report details the complete range of sealants & glues technologies used in traumatic, surgical and other wound closure, from tapes, sutures and staples to hemostats, fibrin sealants/glues and medical adhesives. The report examines the clinical and technology developments underlying this huge and rapidly growing worldwide market, with data on products in development and on the market; market size and forecast; competitor market shares; competitor profiles; and market opportunity. This report is a market and technology assessment and forecast of products in wound closure. The report details the current and emerging products, technologies and markets involved in wound closure and sealing using sutures and staples, tapes, hemostats, fibrin and sealant products and medical adhesives. The report provides a worldwide current and annual forecast to 2011 of the markets for these technologies, with particular emphasis on the market impact of new technologies through the coming decade. The report provides specific forecasts and shares of the worldwide market by segment for the U.S., Europe (United Kingdom, German, France, Italy, BeNeLux), Latin America, Japan and Rest of World.

The report provides background data on the surgical, disease and traumatic wound patient populations targeted by current technologies and those under development, and the current clinical practices in the management of these patients, including the dynamics among the various clinical specialties or subspecialties vying for patient population and facilitating or limiting the growth of technologies. The report establishes the current worldwide market size for major technology segments as a baseline for and projecting growth in the market over a ten-year forecast. The report also assesses and projects the composition of the market as technologies gain or lose relative market performance over this period.

See http://www.mediligence.com/rpt/rpt-s145.htm.

Tags: sealant, fibrin, cyanoacrylate

bookmark to